bluebird bio, Inc. (NASDAQ:BLUE) belonging to the Medical sector has declined -4.84% and closed its last trading session at $70.03.
The company reported its last EPS on 9/30/2016 and is expected to report its next EPS on Nov 02 AMC. Currently, the stock has a 1 Year Price Target of $85.69.
The consensus recommendation, according to Zacks Investment research, is 1.43. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 1.5 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1.5 and 1.5 respectively.
bluebird bio, Inc. on 9/30/2016 reported its EPS as $-1.59 with the analysts projecting the EPS of the stock as $-1.44. The company beat the analyst EPS Estimate with the difference of $-0.15. This shows a surprise factor of -10.4%.
Many analysts have provided their estimated foresights on bluebird bio, Inc. Earnings, with 14 analysts believing the company would generate an Average Estimate of $-1.51. Whereas they predicted High and Low Earnings Estimate as $-0.55 and $-1.77 respectively. While in the same Quarter Previous year, the Actual EPS was $-1.18.
Analysts are also projecting an Average Revenue Estimate for bluebird bio, Inc. as $1.78 Million in the Current Quarter. This estimate is provided by 15 analysts. The High Revenue estimate is predicted as 3 Million, while the Low Revenue Estimate prediction stands at 1 Billion. The company’s last year sales total was 1.32 Million.
The Company got Initiated by Cantor Fitzgerald on 3-Jun-16 to Hold.
Insider Trades for bluebird bio, Inc. show that the latest trade was made on 2 Oct 2016 where Sullivan (Eric), the Officer completed a transaction type “Sell” in which 416 shares were traded at a price of $67.
42 Insider Sales transactions were made totaling 544176 shares traded.
13 analysts projected Price Targets for bluebird bio, Inc.. The analysts believe that the company stock price could grow as high as $135. The Low Price target projection by analysts is $42 and the Mean Price Target is $85.69.
bluebird bio, Inc. (NASDAQ:BLUE) has the market capitalization of $2.62 Billion. The company rocked its 52-Week High of $99.7 on Nov 4, 2015 and touched its 52-Week Low of $35.37 on May 12, 2016. The stock has Return on Assets (ROA) of -20.8 percent. Return on Equity (ROE) stands at -24.8% and Return on Investment (ROI) of -18.5 percent.
The stock is currently showing YTD performance of 9.05 Percent. The company has Beta Value of 1.81 and ATR value of 3.96. The Weekly and Monthly Volatility stands at 6.23% and 5.64%.
Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts.